Recombinant Rat IL-17A/F Heterodimer Protein

RecombinantRat IL‑17A/FHeterodimer (Catalog #9340-IL) induces IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. The ED50for this effect is 3-18 ng/mL.

• Reactivity: Rt
• Applications: Bioactivity

Recombinant Rat IL-17A/F Heterodimer Protein Summary

• Details of Functionality: Measured by its ability to induce IL-6 secretion by NIH‑3T3 mouse embryonic fibroblast cells. Yao, Z. et al. (1995) Immunity 3:811. The ED₅₀ for this effect is 3-18 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived rat IL-17A/F Heterodimer protein
  

  Rat IL-17A (Ala18-Ser150 (Ile46Leu)) Accession # Q61453

  Rat IL-17F (Arg29-Ala161) Accession # Q5BJ95
  N-terminus	C-terminus

• Accession #: Q61453 (IL-17A) & Q5BJ95 (IL-17F)
• N-terminal Sequence: Ala18 (IL-17A) & Arg29 (IL-17F)
• Structure / Form: Disulfide-linked heterodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 15 kDa (IL-17A) & 15 kDa (IL-17F).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 12-30 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat IL-17A/F Heterodimer Protein

• CTLA8
• CTLA8cytotoxic T-lymphocyte-associated serine esterase 8
• Cytotoxic T-lymphocyte-associated antigen 8
• Cytotoxic T-Lymphocyte-Associated Protein 8
• IL17
• IL-17
• IL-17A
• IL-17A/F Heterodimer
• interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8)
• interleukin 17A
• interleukin-17A

Background

Rat IL-17A/F is an approximately 37 kDa, secreted, disulfide-linked glycosylated heterodimeric protein comprised of two members of the IL-17 family of cytokines, IL-17A and IL-17F (1, 2). Members of this family demonstrate a structural motif termed a cysteine knot that also characterizes a large superfamily of growth factors such as TGF-beta (1). Although most cysteine knot superfamily members use three intrachain disulfide bonds to create a knot, IL-17 family molecules generate the same structural form with only two disulfide links (1, 3-5). Mature rat IL-17A and IL-17F share 60% and 59% amino acid sequence identity with human and 61% and 90% with mouse IL-17A and IL-17F, respectively. They also share 50% aa sequence identity with each other (1). IL-17A/F heterodimer and the IL-17A and IL-17F homodimers are produced by IL-23 activated Th17 cells (1, 6-10, 14). The widely expressed receptors IL-17 RA and IL-17 RC form a heterodimer for the binding of
IL-17A and IL-17F, as well as the heterodimeric IL-17A/F (6, 11, 12). IL-17A/F is a biologically active protein that induces chemokine production and airway neutrophilia with intermediate potency between IL-17A (most potent) and IL-17F (least potent) (7, 12). It is up-regulated in immune cells during inflammatory arthritis and contributes to disease severity (13).

1. Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
2. Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
3. Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
4. Kolls, J.K. and A. Linden (2004) Immunity 21:467.
5. Gu, C. et al. (2013) Cytokine 64:477.
6. Cheung, P.F.Y. et al. (2008) J. Immunol. 180:5625.
7. Liang, S.C. et al. (2007) J. Immunol. 179:7791.
8. Ouyang, W. et al. (2008) Immunity 28:454.
9. Steinman, L. (2007) Nat. Med. 13:139.
10. Hunter, C.A. (2005) Nat. Rev. Immunol. 5:521.
11. Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
12. Wright, J.F. et al. (2008) J. Immunol. 181:2799.
13. Sarkar, S. et al. (2014) Clin. Exp. Immunol. 177:652.
14. Spolski, R. et al. (2009) Eur. J. Immunol. 3: 658.

Publications for IL-17A/F Heterodimer (9340-IL)(1)

Publication using 9340-IL

• OK Travis, D White, WA Pierce, Y Ge, CY Stubbs, FT Spradley, JM Williams, DC Cornelius Chronic infusion of interleukin-17 promotes hypertension, activation of cytolytic natural killer cells, and vascular dysfunction in pregnant rats Physiol Rep, 2019-04-01;7(7):e14038. 2019-04-01 [PMID: 30963715] (In Vivo, Rat)

Bioinformatics

• Uniprot:
  • Q61453 (IL-17A) & Q5BJ95 (IL-17F)()